Effect of ubiquinol on cardiorespiratory fitness during high-altitude acclimatization and de-acclimatization in healthy adults: the Shigatse CARdiorespiratory fitness study design.
cardiopulmonary exercise test
cardiorespiratory fitness
clinical trial
high altitude
study design
ubiquinol
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
12
2022
accepted:
10
07
2023
medline:
10
8
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
epublish
Résumé
Cardiorespiratory function influences exercise capacity and is an important determinant of high-altitude adaptation. Some studies have investigated the characteristics of changes in cardiorespiratory fitness during high-altitude acclimatization. However, studies on changes in cardiorespiratory fitness during high-altitude de-acclimatization are still lacking and have not yet been elucidated. Furthermore, few drugs have been studied to improve cardiorespiratory function during both processes. The Shigatse CARdiorespiratory Fitness (SCARF) study is a single-center, randomized, double-blind, placebo-control clinical trial to explore the effects of ubiquinol on cardiorespiratory fitness during high-altitude acclimatization and de-acclimatization in healthy adults. Participants will be randomly assigned 1:1 to ubiquinol 200 mg daily or a placebo for 14 days before departure until the end of data collection after return in 7 days. Cardiorespiratory fitness is the primary outcome, while acute mountain sickness and high-altitude de-acclimatization symptoms are secondary endpoints. In addition, laboratory measurements, including routine blood tests and serological measurements, will be performed. To the best of our knowledge, the SCARF study will be the first to reveal the changes in the cardiorespiratory fitness characteristics during high-altitude acclimatization and de-acclimatization. Furthermore, the results of this study will contribute to exploring whether ubiquinol supplementation could be beneficial for endurance exercise capacity at different altitudes and help improve adaptation to acute hypoxia and de-acclimatization.
Identifiants
pubmed: 37560117
doi: 10.3389/fcvm.2023.1129144
pmc: PMC10407655
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1129144Informations de copyright
© 2023 Yang, Ye, Liu, Sun, Yu, Lv, Wu, Zhang, Gu, He, Wang and Huang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am Rev Respir Dis. 1984 Feb;129(2 Pt 2):S49-55
pubmed: 6421218
Eur Respir Rev. 2019 Dec 18;28(154):
pubmed: 31852745
Eur J Appl Physiol. 2007 Aug;100(6):663-73
pubmed: 17534646
Am J Respir Crit Care Med. 2000 Jan;161(1):309-29
pubmed: 10619836
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Eur Heart J. 2002 May;23(10):806-14
pubmed: 12009721
Cochrane Database Syst Rev. 2019 Apr 23;4:CD013315
pubmed: 31012483
Eur Heart J. 2022 Sep 1;43(33):3132-3145
pubmed: 35639660
Eur Heart J. 2001 Aug;22(16):1496-503
pubmed: 11482923
Front Cardiovasc Med. 2022 May 23;9:856749
pubmed: 35677688
Circ Heart Fail. 2012 Sep 1;5(5):621-6
pubmed: 22899767
Med Sci Sports Exerc. 2011 Aug;43(8):1575-81
pubmed: 21681120
Front Pharmacol. 2022 Aug 24;13:883251
pubmed: 36091835
J Travel Med. 2012 Sep-Oct;19(5):298-307
pubmed: 22943270
Neuro Endocrinol Lett. 2009;30(4):470-6
pubmed: 20010505
Br J Sports Med. 2023 Jul;57(14):906-913
pubmed: 36898769
Mitochondrion. 2007 Jun;7 Suppl:S78-88
pubmed: 17482886
Cent Eur J Public Health. 2020 Jun;28(2):120-123
pubmed: 32592556
High Alt Med Biol. 2010 Winter;11(4):325-32
pubmed: 21190501
Mol Aspects Med. 1997;18 Suppl:S283-90
pubmed: 9266538
Circulation. 2010 Jul 13;122(2):191-225
pubmed: 20585013
Neuro Endocrinol Lett. 2009;30(4):462-9
pubmed: 20010493
Nutrition. 2008 Apr;24(4):293-9
pubmed: 18272335
BMC Nephrol. 2015 Nov 03;16:183
pubmed: 26531095
Eur J Appl Physiol. 2006 Mar;96(4):404-12
pubmed: 16311764
Antioxidants (Basel). 2022 Sep 30;11(10):
pubmed: 36290691
Eur Respir J. 2010 Nov;36(5):1049-55
pubmed: 20378601
Pharmacol Res Perspect. 2016 May 19;4(3):e00203
pubmed: 27433337
Int J Cardiol. 2014 Oct 20;176(3):1348-9
pubmed: 25135333
J Affect Disord. 2019 Jun 1;252:122-129
pubmed: 30981055
Am Heart J. 2006 Feb;151(2):367.e7-367.e16
pubmed: 16442901
Curr Drug Metab. 2016;17(4):345-58
pubmed: 26526835
J Appl Physiol Respir Environ Exerc Physiol. 1979 Nov;47(5):954-60
pubmed: 511720
Med Sci Sports Exerc. 2016 Apr;48(4):625-32
pubmed: 26587846
Am J Respir Crit Care Med. 2003 Jan 15;167(2):211-77
pubmed: 12524257
Am Heart J. 2018 Feb;196:156-162
pubmed: 29421008
Free Radic Biol Med. 2021 Mar;165:282-288
pubmed: 33482334
Front Cardiovasc Med. 2022 Jun 10;9:866093
pubmed: 35757324
Circulation. 2020 Aug 18;142(7):e101-e118
pubmed: 32686505
Circulation. 2013 Aug 20;128(8):873-934
pubmed: 23877260
PLoS One. 2013 May 01;8(5):e62072
pubmed: 23650508
J Am Coll Cardiol. 2001 Jan;37(1):153-6
pubmed: 11153730
J Appl Physiol (1985). 1986 Jun;60(6):2020-7
pubmed: 3087938
Prog Cardiovasc Dis. 2010 May-Jun;52(6):456-66
pubmed: 20417339
BMJ. 2012 Oct 31;345:e7077
pubmed: 23114063
J Am Coll Cardiol. 2012 Jan 3;59(1):9-15
pubmed: 22192662
Mayo Clin Proc. 2021 Jan;96(1):32-39
pubmed: 33413833
J Am Coll Cardiol. 2021 Feb 9;77(5):609-619
pubmed: 33538259
High Alt Med Biol. 2018 Mar;19(1):4-6
pubmed: 29583031
Antioxidants (Basel). 2022 Jul 13;11(7):
pubmed: 35883851
Circulation. 2016 Jun 14;133(24):e694-711
pubmed: 27143685
J Immunol Res. 2019 Nov 15;2019:4521231
pubmed: 31828172
Am Heart J. 2017 Feb;184:55-61
pubmed: 27892887
High Alt Med Biol. 2014 Apr;15(1):46-51
pubmed: 24673534
Mayo Clin Proc. 2018 Mar;93(3):333-336
pubmed: 29174511